{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 30,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/22",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.85,
        "x": 0.11,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Single-Dose Part: GH001 6 mg (n=8+2 placebo), GH001 12 mg (n=8+2 placebo), GH001 18 mg (n=8+2 placebo). IDR Part: GH001 IDR 6, 12, 18 mg to achieve PE (up to 3 doses, 1h interval, n=8), GH001 IDR 6, 12, 18 mg to achieve PE (up to 3 doses, 2h interval, n=8). HV (n=30) splits into Single-Dose, then HV (n=16) splits into IDR.",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6215d5d1-639d-4ec8-9f30-f90ed306c301",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.73,
        "x": 0.17,
        "y": 0.63
      },
      "kind": "diagram",
      "text": "GH001 Administration, Day 7 (Safety, Cognitive function), Day 30 (Safety)",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b19b57bd-fd0d-4eb2-adbb-b031e98b83fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.149,
        "x": 0.818,
        "y": 0.03
      },
      "kind": "image",
      "text": "GH Research",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01ed66ac-4173-4786-abe2-5c40b4bfdadd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.069,
        "y": 0.885
      },
      "kind": "legend",
      "text": "HV, Healthy Volunteer; PE, Peak Experience; IDR, Individualized Dosing Regimen",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9853eab6-7d57-46e1-b7e7-32a016ba0af9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.069,
        "y": 0.756
      },
      "kind": "list",
      "text": "Key Assessments:\nSafety\nPharmacokinetics\nPE Scale\nCognitive function",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23985182-7434-4642-8a5b-919811e9dde4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.17,
        "x": 0.788,
        "y": 0.33
      },
      "kind": "list",
      "text": "Primary Endpoint:\nPharmacokinetic profile of mebufotenin (5-MeO-DMT) and bufotenine",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "726eb4b4-eb1a-4a78-a662-4f959c9276b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.02,
        "x": 0.936,
        "y": 0.95
      },
      "kind": "other",
      "text": "22",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d91e01f-b0ad-487f-aea8-026cd8424070",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.16,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "paragraph",
      "text": "2023© GH Research PLC",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78201991-13f6-4c27-9b38-c999dcdfdc1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.74,
        "x": 0.069,
        "y": 0.073
      },
      "kind": "title",
      "text": "Design of Phase 1 Clinical Pharmacology Trial in Healthy Volunteers (GH001-HV-103)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48735d27-e3de-4953-bfb6-cf5b7ceda2b6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}